Arbutus Biopharma Corporation announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2023 taking place June 21 - 24, 2023 in Vienna, Austria. Key Findings: AB-729 treatment in virally suppressed cHBV patients was well tolerated and led to mean HBsAg increases of >1.6 log10 after 24 weeks of treatment, comparable to other AB-729 studies. HBsAg levels.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.73 USD | +0.37% | +0.37% | +9.20% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.20% | 492M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- ABUS Stock
- News Arbutus Biopharma Corporation
- Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023